IACMI will nearly double its workforce programs to a total of more than 100 sites by 2030, offering pathways into high-demand ...

For years, the promise of AI in software engineering has delivered incremental gains. Most organizations have adopted an ...

Novel conditionally active T cell engagers sourced from proprietary BiTAC® platform are at the basis of advanced partnering initiatives and development activities ...

VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for its lead BiTAC ® T-cell engager ...

CNW/ - BoomerangFX, the global AI-powered clinic software and marketing-automation company purpose-built for private-pay ...

VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager ...

The companies attributed this speed to a deep software-hardware co-development process that actively used OpenAI’s own models ...

June 1 marked the launch of a new Division of Design at the Meadows School of the Arts. Combining Creative Computing, the Master of Arts in Design and Innovation (MADI) and SMU Gu ...

The Government Accountability Office's (GAO) latest report of major defense acquisition programs found that while several ...

AI systems require large amounts of user data to function, but privacy laws limit how it can be stored and where it can be processed.

Good morning, everyone, and welcome to Part 1 of Arrowhead Pharmaceuticals' 2026 Summer Series of R&D webinars. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be ...

VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced that the Company has moved into additional laboratory space at its existing R&D site ...